Zeina Rabi, MD
Clinical Neurophysiology · Hinsdale, ILNPI 1205179744
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 331 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations.
Across 331 payments — averaging $20.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$1K
- AbbVie$1K
- Bristol Myers Squibb$639
- Teva Pharmaceuticals USA, Inc.$629
- Acadia Pharmaceuticals Inc$277
- Genentech USA, Inc.$204
- plus $2K from 33 others
What the payments were for
- Food & beverage$6,72699%
- Education$501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 80 | $1,474 |
| AbbVie | 68 | $1,334 |
| Bristol Myers Squibb | 34 | $639 |
| Teva Pharmaceuticals USA, Inc. | 28 | $629 |
| Acadia Pharmaceuticals Inc | 16 | $277 |
| Genentech USA, Inc. | 8 | $204 |
| Argenx US, Inc. | 7 | $176 |
| Novartis | 8 | $172 |
| UCB, Inc. | 5 | $168 |
| Amgen(2 entities) | 8 | $162 |
| Pfizer | 7 | $147 |
| Banner Life Sciences, LLC | 7 | $136 |
| SK Life Science, Inc. | 4 | $121 |
| Lilly USA, LLC | 4 | $116 |
| Lundbeck LLC | 3 | $109 |
| AstraZeneca | 5 | $101 |
| EMD Serono, Inc. | 3 | $80 |
| TG Therapeutics, Inc. | 2 | $80 |
| Livanova USA, Inc. | 3 | $74 |
| Kyowa Kirin, Inc. | 3 | $72 |
| Biohaven Pharmaceuticals, Inc. | 3 | $68 |
| Supernus Pharmaceuticals, Inc. | 4 | $53 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $42 |
| E.r. Squibb & Sons, L.L.C. | 2 | $38 |
| Currax Pharmaceuticals LLC | 2 | $33 |
| Johnson & Johnson | 1 | $31 |
| Assertio Therapeutics, Inc. | 2 | $26 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| Sanofi | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 1 | $21 |
| Akcea Therapeutics, Inc. | 1 | $21 |
| Cala Health, Inc. | 1 | $19 |
| Impel Pharmaceuticals Inc. | 1 | $18 |
| Acorda Therapeutics, Inc | 1 | $17 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
| Abbott | 1 | $15 |
| Upsher-smith Laboratories LLC | 1 | $15 |
| Cycle Pharmaceuticals Inc | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TECFIDERA$119
How this compares
Too few clinical neurophysiology providers in Illinoisto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 38 | $61,163 |
| UbrelvyUbrogepant | 27 | $37,737 |
| Aimovig AutoinjectorErenumab-Aooe | 22 | $20,549 |
| QuliptaAtogepant | 12 | $13,123 |
| Levetiracetam | 70 | $2,407 |
| Memantine Hcl ErMemantine Hcl | 30 | $2,296 |
| Donepezil Hcl | 67 | $2,091 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 82 | $1,597 |
| Memantine Hcl | 66 | $1,561 |
| Lacosamide | 11 | $1,203 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 31 | $1,153 |
| Gabapentin | 87 | $1,128 |
| Primidone | 26 | $837 |
| Quetiapine Fumarate | 27 | $572 |
| Atorvastatin Calcium | 46 | $400 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $147 | $61,16338 claims |
| AbbVieUbrelvy, Qulipta | $1,334 | $50,86039 claims |
| Upsher-smith Laboratories LLCTopiramate | $15 | $19229 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Illinoison file to place this against a meaningful peer group, so we don't.
Other clinical neurophysiology in Hinsdale
- Micheal MackenChicago$555K
- Sumayyah AbumuradChicago$85K
- Abdallah HamdallahPalos Heights$12K
- Akash PatelChicago$10K
- Clarissa LiewChampaign$9K
- Mir YadullahiChicago$2K
- Abdullah AlamChicago$2K
- Delphi BaruaDecatur$982
- Suemin YoonLake Forest$532
- Diana MnatsakanovaChicago$375
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.